Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megumi Fukuoka

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Breast Journal|May 30, 2020
Breast castleman diseaseMegumi Fukuoka, Takayuki Ueno, Kazuyo Yoshida, et al.
Cancer Science|April 13, 2022
The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancerMegumi Fukuoka, Yuichi Ichikawa, Tomo Osako, et al.
Molecular Systems Biology|November 3, 2021
Modeling population size independent tissue epigenomes by ChIL-seq with single thin sectionsKazumitsu Maehara, Kosuke Tomimatsu, Akihito Harada, et al.
BMJ Open|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)Yukinori Ozaki, Shohei Koyama, Satoshi Morita, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Breast Journal|May 30, 2020
Breast castleman diseaseMegumi Fukuoka, Takayuki Ueno, Kazuyo Yoshida, et al.
Cancer Science|April 13, 2022
The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancerMegumi Fukuoka, Yuichi Ichikawa, Tomo Osako, et al.
Molecular Systems Biology|November 3, 2021
Modeling population size independent tissue epigenomes by ChIL-seq with single thin sectionsKazumitsu Maehara, Kosuke Tomimatsu, Akihito Harada, et al.
BMJ Open|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)Yukinori Ozaki, Shohei Koyama, Satoshi Morita, et al.
Pageof 1